Pharmaceutical care for severe and critically ill patients with COVID-19
Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences - 49(2020), 2 vom: 25. Mai, Seite 158-169 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Jiang, Saiping [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 12.05.2020 Date Revised 05.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3785/j.issn.1008-9292.2020.03.01 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309748437 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309748437 | ||
| 003 | DE-627 | ||
| 005 | 20231225134610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3785/j.issn.1008-9292.2020.03.01 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309748437 | ||
| 035 | |a (NLM)32391659 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Jiang, Saiping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical care for severe and critically ill patients with COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2020 | ||
| 500 | |a Date Revised 05.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Li, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Ru, Renping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chunhong |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Yuefeng |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Rongrong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaojuan |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Hongliu |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Jifang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jianying |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Xiaoyang |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Yunqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences |d 2002 |g 49(2020), 2 vom: 25. Mai, Seite 158-169 |w (DE-627)NLM123207037 |x 1008-9292 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2020 |g number:2 |g day:25 |g month:05 |g pages:158-169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3785/j.issn.1008-9292.2020.03.01 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2020 |e 2 |b 25 |c 05 |h 158-169 | ||